Ultragenyx Pharmaceutical Inc [RARE] stock is trading at $27.66, up 0.18%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RARE shares have gain 4.61% over the last week, with a monthly amount drifted -24.26%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On June 06, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $67 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $77 on April 22, 2024. Wells Fargo initiated its recommendation with a Overweight and recommended $72 as its price target on December 08, 2023. In a note dated June 06, 2023, Evercore ISI upgraded an Outperform rating on this stock and boosted its target price from $60 to $80.
Ultragenyx Pharmaceutical Inc [RARE] stock has fluctuated between $25.81 and $60.37 over the past year. Currently, Wall Street analysts expect the stock to reach $89.5 within the next 12 months. Ultragenyx Pharmaceutical Inc [NASDAQ: RARE] shares were valued at $27.66 at the most recent close of the market. An investor can expect a potential return of 223.57% based on the average RARE price forecast.
Analyzing the RARE fundamentals
Ultragenyx Pharmaceutical Inc [NASDAQ:RARE] reported sales of 590.69M for the trailing twelve months, which represents a growth of 27.99%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -0.87%, Pretax Profit Margin comes in at -0.93%, and Net Profit Margin reading is -0.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -1.86 and Total Capital is -0.5. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 27.21 points at the first support level, and at 26.77 for the second support level. However, for the 1st resistance point, the stock is sitting at 28.29, and for the 2nd resistance point, it is at 28.93.
Ratios To Look Out For
For context, Ultragenyx Pharmaceutical Inc’s Current Ratio is 2.40. Further, the Quick Ratio stands at 2.24, while the Cash Ratio is 0.44. Considering the valuation of this stock, the price to sales ratio is 4.43, the price to book ratio is 17.98.
Transactions by insiders
Recent insider trading involved Sanders Corazon (Corsee) D., Director, that happened on Jun 20 ’25 when 2405.0 shares were sold. Director, CORAZON D. SANDERS completed a deal on Jun 20 ’25 to buy 2405.0 shares. Meanwhile, EVP and Chief Medical Officer Crombez Eric sold 520.0 shares on May 05 ’25.
